PT - JOURNAL ARTICLE AU - Sophie Owen AU - Faria Hossain AU - Prakash Ghosh AU - Rajashree Chowdhury AU - Md. Sakhawat Hossain AU - Christopher Jewell AU - Isra Cruz AU - Albert Picado AU - Dinesh Mondal AU - Emily R. Adams TI - Detection of asymptomatic <em>Leishmania</em> infection in Bangladesh by novel antigen and antibody diagnostic tools shows strong association with PKDL patients AID - 10.1101/2020.05.26.20113431 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.26.20113431 4099 - http://medrxiv.org/content/early/2020/05/27/2020.05.26.20113431.short 4100 - http://medrxiv.org/content/early/2020/05/27/2020.05.26.20113431.full AB - Background Asymptomatic Leishmania infections outnumber clinical infections on the Indian sub-continent (ISC) where disease reservoirs are anthroponotic. Diagnostics which detect active asymptomatic infection, which are suitable for monitoring and surveillance, may be of benefit to the visceral leishmaniasis (VL) elimination campaign on the ISC.Methodology/Principal Findings Quantitative polymerase chain reaction (qPCR), loop mediated isothermal amplification (LAMP), the direct agglutination test (DAT), and the Leishmania antigen ELISA were carried out on blood and urine samples collected from 720 household and neighbouring contacts of 276 VL and post kala-azar dermal leishmaniasis (PKDL) index cases, with no symptoms or history of VL and PKDL, in endemic regions of Bangladesh between September 2016 and March 2018. Of the 720 contacts of index cases, asymptomatic infection was detected in 69 (9.6%) participants by a combination of qPCR (1.0%), LAMP (2.1%), DAT (3.9%), and Leishmania antigen ELISA (3.3%). Only 1 (0.1%) participant was detected positive by all 4 diagnostic tests. Poor agreement between tests was calculated using Cohen’s kappa (k) statistics, however the Leishmania antigen ELISA and DAT in combination capture all participants positive by more than one test. We find strong evidence for association between the index case being a PKDL case (OR 1.94, p = 0.009), specifically macular PKDL (OR 2.12, p = 0.004) and being positive for at least one of the four tests.Conclusions/Significance Leishmania antigen ELISA detects active asymptomatic infection, requires a non-invasive sample, and therefore may be of benefit for monitoring transmission and surveillance in an elimination setting in combination with serology. Development of an antigen detection test in RDT format would be of benefit to the elimination campaign.Author summary Infection with the parasite Leishmania donovani can lead to an asymptomatic infection with only around 5% of asymptomatics converting to visceral leishmaniasis the clinical manifestation of the infection. Serological assays detect anti-Leishmania antibodies and therefore cannot distinguish between past and active infection. Molecular assays and those which detect Leishmania antigens detect active infection. Since the signing of a memorandum of understanding in 2005, visceral leishmaniasis has been targeted for elimination in India, Nepal and Bangladesh. In an elimination setting such as Bangladesh, where disease reservoirs are anthroponotic, a relatively simple test such as the Leishmania antigen ELISA which requires a non-invasive urine sample, may be of benefit in combination with serology for surveillance and monitoring of Leishmania transmission. Development of an antigen test into a field compatible rapid diagnostic test would be of further benefit to the elimination campaign.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was received for this study from the German Federal Ministry of Education and Research (BMBF) through the KfW Entwicklungs bank (KfW grant reference number 202060457, Development of Products for the Prevention, Diagnosis and Treatment of Neglected and Poverty Related Diseases; https://www.bmbf.de/en, received by FIND), MRC-DTP (grant reference number MR/N013514/1; https://mrc.ukri.org/, received by ERA), and Wellcome Seed fund (grant reference number 108080/Z/15/Z; https://wellcome.ac.uk/, received by ERA). FIND is grateful to its donors, public and private, who have helped bring innovative new diagnostics for diseases of poverty. A full list of FIND's donors can be found at: https://www.finddx.org/donors/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethical Review Committee (ERC) of the ICDDR,B (PR-14093).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request.